Navigation Links
Sales of Stem Cell Products Expected to Reach $87 Million in 2008, Leading Medical Industry Analyst Says
Date:2/1/2008

Robin R. Young to Provide 10-Year Forecast at 3rd Annual Stem Cell Summit

on Feb. 26

PHILADELPHIA, Feb. 1 /PRNewswire/ -- Stem cell product sales in the United States totaled $36 million in 2007, a 119 percent increase from the previous year, and are expected to reach $87 million, a 144 percent increase, in 2008, according to Robin R. Young, CFA, a medical industry analyst ranked as one of The Wall Street Journal's "Best on the Street" and among Institutional Investor's top-10.

The projections are based on Young's analysis of adult and human embryonic stem cell products currently sold or in development for the orthopedics, cardiovascular, anti-inflammatory, diabetes, nerve repair and dental markets.

"In recent months we've seen the largest stem cell product purchases in this fast-growing industry," Young said. "Physicians have already treated several thousands of patients in the United States with stem cell products. Moreover, the results of the clinical trials involving these types of products have been very impressive. This is a transformational year with the first-ever human embryonic stem cell products expected to enter the clinic."

Young will provide additional market data at the 3rd Annual Stem Cell Summit, which will take place Feb. 26 in New York City. The meeting is slated to be the largest gathering of stem cell company executives, scientists, investors and physicians. Attendees will learn about the investment opportunities in the stem cell marketplace, the groundbreaking stem cell products physicians are using today, and the growing market potential in terms of revenues. More information, including attendee registration details, is available at http://www.stemcellsummit.com.

Young has more than 25 years of experience as an analyst. He is the president of RRY Publications and the organizer of the Stem Cell Summit.

<
'/>"/>
SOURCE RRY Publications
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
2. Mark Ostrowski Joins GenVault as Vice President of Sales and Marketing
3. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
4. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
5. /CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
8. ForceLogix, Innovex Win Sales Operational Performance Award
9. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 Ryan Carfley , Managing ... to sit down with Bryan Hamilton, the publisher of the ... discuss talent in the Research Triangle region of North Carolina. ... highlighted at the roundtable include the role of social ... of work/life balance and the unique role that Millennials play ...
(Date:10/27/2014)... -- The Italian company Roadrunnerfoot has ... its artificial "lower limb", after the German giant ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... judgement has arrived: Roadrunnerfoot, the small Italian company ... prostheses with composite materials, has won against global ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information says ... Ebola concern in the United States ... The healthcare market researcher said the FDA,s Emergency Use Authorization ... diagnostic tests for the detection of the Ebola virus ... useful.  Kalorama routinely assess the IVD industry and its ...
(Date:10/27/2014)... MA (PRWEB) October 27, 2014 ... profit. SoundConnect , an industry leading unified ... its partners and agents to deliver cloud-based audio ... accelerate growth opportunities. , With SoundConnect’s Q4 ... every twenty-five video and/or web conferencing licenses sold, ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3SoundConnect Unveils Q4 Partner Incentives 2
... as an acceptable primary endpoint, for ... April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... reached an agreement with the U.S. Food and Drug ... 3 registration trial of OGX-011, its lead product candidate ...
... containing microneedles has proven just as effective at ... immunization. A team of researchers at Emory University ... new microneedle skin patch method of delivering flu ... people because of decreased pain, increased convenience, lower ...
... of $264.5 million grows 7.8% year-over-year- Operating margin ... Net quarterly book-to-bill ratio equates to 1.25BOSTON, April ... PRXL ) today announced its financial results for ... three months ended March 31, 2009, PAREXEL,s consolidated ...
Cached Biology Technology:OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6Flu vaccine given in microneedle skin patches proves effective in mice 2Flu vaccine given in microneedle skin patches proves effective in mice 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 2PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 5PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 6PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 7PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 8PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 9PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 10PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 11PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 12PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 13PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 14PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 15
(Date:10/29/2014)... in New York City on September 19, 2014, leading ... Society Professor of Genome Sciences and Medicine at the ... of Philosophy of Tel Aviv University, was awarded the ... In addition to her honorary degree from TAU, Prof. ... School of Medicine, and for the past 18 years ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... Cancer Genomics of the Kidney consortium ( CAGEKID ... and exposure to aristolochic acid, an ingredient in ... Nature Communications , have important implications for public ... people every year, and in Central Europe incidence ... the International Cancer Genome Consortium (ICGC), has been ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... Jewish Medical and Research Center report in the March ... proteins, known as fibulins 3 and 5, slow the ... vessels from sprouting. The proteins are promising candidates for ... fibulin proteins, which regulate cell proliferation, migration and invasion. ...
... A new UCLA imaging study shows that age-related breakdown ... wiring, correlates strongly with the presence of a key ... are detailed in the January edition of the peer-reviewed ... growing body of evidence that myelin breakdown is a ...
... in the home, but the presence of gas stresses out ... from the University of Nottingham have found that changes in ... warning of leaks in natural gas pipelines. "Our study ... monitor gas leaks via the spectrum of reflected light from ...
Cached Biology News:Proteins stop blood-vessel and tumor growth in mice 2Imaging study links key genetic risk for Alzheimer's disease to myelin breakdown 2Plants used to detect gas leaks, from outer space! 2